{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:48:33Z","timestamp":1784864913992,"version":"3.55.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yarmouk University, Irbid, Jordan"},{"name":"Wilhelm-Sander-Stiftung Munich","award":["2015.102.1"],"award-info":[{"award-number":["2015.102.1"]}]},{"name":"HeadsUp, Oxford, UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02129-8","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T10:17:11Z","timestamp":1750328231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Src family kinase inhibitor drug Dasatinib and glucocorticoids display synergistic activity against tongue squamous cell carcinoma and reduce MET kinase activity"],"prefix":"10.1186","volume":"23","author":[{"given":"Ali N. A.","family":"Hmedat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Doondeea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan M.","family":"Feller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lewitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"2129_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41368-023-00249-w","volume":"15","author":"Y Tan","year":"2023","unstructured":"Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, et al. Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci. 2023;15:44.","journal-title":"Int J Oral Sci"},{"key":"2129_CR2","first-page":"5681","volume":"17","author":"L Zhu","year":"2019","unstructured":"Zhu L, Wang Y, Li R, Liu A, Zhang X, Zuo C, et al. Surgical treatment of early tongue squamous cell carcinoma and patient survival. Oncol Lett. 2019;17:5681\u20135.","journal-title":"Oncol Lett"},{"key":"2129_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijom.2021.04.006","volume":"51","author":"H Nemade","year":"2022","unstructured":"Nemade H, Chaitanya SA, Kumar S, A AK, Rao TS, Rao SLMCS. Oncological outcomes of total glossectomy procedure for advanced tongue cancer: a single-centre experience. Int J Oral Maxillofac Surg. 2022;51:152\u20138.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"2129_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1308\/rcsann.2020.0100","volume":"102","author":"R Katna","year":"2020","unstructured":"Katna R, Bhosale B, Sharma R, Singh S, Deshpande A, Kalyani N. Oncological outcomes in patients undergoing major glossectomy for advanced carcinoma of the oral tongue. Ann R Coll Surg Engl. 2020;102:514\u20138.","journal-title":"Ann R Coll Surg Engl"},{"key":"2129_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13073-015-0219-2","volume":"7","author":"AL Vettore","year":"2015","unstructured":"Vettore AL, Ramnarayanan K, Poore G, Lim K, Ong CK, Huang KK, et al. Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. Genome Med. 2015;7:98.","journal-title":"Genome Med"},{"key":"2129_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrc.2018.11","volume":"18","author":"CR Leemans","year":"2018","unstructured":"Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18:269\u201382.","journal-title":"Nat Rev Cancer"},{"key":"2129_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-022-01297-0","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Tie Y, Alu A, Ma X, Shi H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct Target Ther. 2023;8:31.","journal-title":"Signal Transduct Target Ther"},{"key":"2129_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16070888","volume":"16","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Yao Z, Lin Y, Zhang H. From Tyrosine kinases to tyrosine phosphatases: new therapeutic targets in cancers and beyond. Pharmaceutics. 2024;16: 888.","journal-title":"Pharmaceutics"},{"key":"2129_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512222","volume":"24","author":"N Bou Antoun","year":"2023","unstructured":"Bou Antoun N, Chioni A-M. Dysregulated signalling pathways driving anticancer drug resistance. Int J Mol Sci. 2023;24: 12222.","journal-title":"Int J Mol Sci"},{"key":"2129_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","volume":"6","author":"LC Kim","year":"2009","unstructured":"Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009;6:587\u201395.","journal-title":"Nat Rev Clin Oncol"},{"key":"2129_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1074\/jbc.271.2.695","volume":"271","author":"JH Hanke","year":"1996","unstructured":"Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem. 1996;271:695\u2013701.","journal-title":"J Biol Chem."},{"key":"2129_CR12","doi-asserted-by":"publisher","first-page":"vi42","DOI":"10.1093\/annonc\/mdm223","volume":"18 Suppl 6","author":"A Olivieri","year":"2007","unstructured":"Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol. 2007;18 Suppl 6:vi42\u201346.","journal-title":"Ann Oncol"},{"key":"2129_CR13","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/cncr.25769","volume":"117","author":"HD Brooks","year":"2011","unstructured":"Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011;117:2112\u20139.","journal-title":"Cancer"},{"key":"2129_CR14","first-page":"249","volume":"31","author":"MG Fury","year":"2011","unstructured":"Fury MG, Baxi S, Shen R, Kelly KW, Lipson BL, Carlson D, et al. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res. 2011;31:249\u201353.","journal-title":"Anticancer Res"},{"key":"2129_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081157","volume":"8","author":"F Hermida-Prado","year":"2019","unstructured":"Hermida-Prado F, Villaronga M\u00c1, Granda-D\u00edaz R, Del-R\u00edo-Ibisate N, Santos L, Hermosilla MA, et al. The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042. J Clin Med. 2019;8: 1157.","journal-title":"J Clin Med"},{"key":"2129_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-1-4939-2895-8_14","volume":"872","author":"MA Pufall","year":"2015","unstructured":"Pufall MA. Glucocorticoids and Cancer. Adv Exp Med Biol. 2015;872:315\u201333.","journal-title":"Adv Exp Med Biol"},{"key":"2129_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2022.07.003","volume":"13","author":"KN Kim","year":"2023","unstructured":"Kim KN, LaRiviere M, Macduffie E, White CA, Jordan-Luft MM, Anderson E, et al. Use of glucocorticoids in patients with cancer: potential benefits, harms, and practical considerations for clinical practice. Pr Radiat Oncol. 2023;13:28\u201340.","journal-title":"Pr Radiat Oncol"},{"key":"2129_CR18","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1083\/jcb.150.6.1375","volume":"150","author":"M Sachs","year":"2000","unstructured":"Sachs M, Brohmann H, Zechner D, M\u00fcller T, H\u00fclsken J, Walther I, et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J Cell Biol. 2000;150:1375\u201384.","journal-title":"J Cell Biol"},{"key":"2129_CR19","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1128\/MCB.20.10.3695-3704.2000","volume":"20","author":"M Itoh","year":"2000","unstructured":"Itoh M, Yoshida Y, Nishida K, Narimatsu M, Hibi M, Hirano T. Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation. Mol Cell Biol. 2000;20:3695\u2013704.","journal-title":"Mol Cell Biol"},{"key":"2129_CR20","doi-asserted-by":"publisher","first-page":"M111 .011635","DOI":"10.1074\/mcp.M111.011635","volume":"10","author":"Z Wu","year":"2011","unstructured":"Wu Z, Doondeea JB, Gholami AM, Janning MC, Lemeer S, Kramer K, et al. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics. 2011;10:M111 .011635.","journal-title":"Mol Cell Proteomics."},{"key":"2129_CR21","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1073\/pnas.0712176105","volume":"105","author":"M Emaduddin","year":"2008","unstructured":"Emaduddin M, Bicknell DC, Bodmer WF, Feller SM. Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. Proc Natl Acad Sci U A. 2008;105:2358\u201362.","journal-title":"Proc Natl Acad Sci U A"},{"key":"2129_CR22","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1002\/j.1460-2075.1994.tb06684.x","volume":"13","author":"R Sakai","year":"1994","unstructured":"Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J. 1994;13:3748\u201356.","journal-title":"EMBO J"},{"key":"2129_CR23","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.febslet.2012.04.029","volume":"586","author":"M Lewitzky","year":"2012","unstructured":"Lewitzky M, Simister PC, Feller SM. Beyond \u201cfurballs\u201d and \u201cdumpling soups\u201d - towards a molecular architecture of signaling complexes and networks. FEBS Lett. 2012;586:2740\u201350.","journal-title":"FEBS Lett"},{"key":"2129_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2015.02.027","volume":"562","author":"MDP Camacho Leal","year":"2015","unstructured":"Camacho Leal MDP, Sciortino M, Tornillo G, Colombo S, Defilippi P, Cabodi S. p130Cas\/BCAR1 scaffold protein in tissue homeostasis and pathogenesis. Gene. 2015;562:1\u20137.","journal-title":"Gene"},{"key":"2129_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00018-009-0213-1","volume":"67","author":"N Tikhmyanova","year":"2010","unstructured":"Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci. 2010;67:1025\u201348.","journal-title":"Cell Mol Life Sci"},{"key":"2129_CR26","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.cellsig.2012.12.019","volume":"25","author":"A Barrett","year":"2013","unstructured":"Barrett A, Pellet-Many C, Zachary IC, Evans IM, Frankel P. p130Cas: a key signalling node in health and disease. Cell Signal. 2013;25:766\u201377.","journal-title":"Cell Signal"},{"key":"2129_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.tcb.2006.03.003","volume":"16","author":"P Defilippi","year":"2006","unstructured":"Defilippi P, Di Stefano P, Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 2006;16:257\u201363.","journal-title":"Trends Cell Biol"},{"key":"2129_CR28","doi-asserted-by":"publisher","first-page":"12247","DOI":"10.1074\/jbc.M115.649947","volume":"290","author":"J Kumbrink","year":"2015","unstructured":"Kumbrink J, Soni S, Laumbacher B, Loesch B, Kirsch KH. Identification of Novel Crk-associated Substrate (p130Cas) Variants with Functionally Distinct Focal Adhesion Kinase Binding Activities. J Biol Chem. 2015;290:12247\u201355.","journal-title":"J Biol Chem"},{"key":"2129_CR29","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.immuni.2012.03.007","volume":"36","author":"D Liu","year":"2012","unstructured":"Liu D, Peterson ME, Long EO. The adaptor protein Crk controls activation and inhibition of natural killer cells. Immunity. 2012;36:600\u201311.","journal-title":"Immunity"},{"key":"2129_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","volume":"18","author":"SK Mitra","year":"2006","unstructured":"Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516\u201323.","journal-title":"Curr Opin Cell Biol"},{"key":"2129_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/BJ20070797","volume":"408","author":"J Bain","year":"2007","unstructured":"Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408:297\u2013315.","journal-title":"Biochem J"},{"key":"2129_CR32","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1021\/cb501048b","volume":"10","author":"KR Brandvold","year":"2015","unstructured":"Brandvold KR, Santos SM, Breen ME, Lachacz EJ, Steffey ME, Soellner MB. Exquisitely specific bisubstrate inhibitors of c-Src kinase. ACS Chem Biol. 2015;10:1387\u201391.","journal-title":"ACS Chem Biol"},{"key":"2129_CR33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/15353702221139183","volume":"248","author":"S Lee","year":"2023","unstructured":"Lee S, Park S, Ryu J-S, Kang J, Kim I, Son S, et al. c-Src inhibitor PP2 inhibits head and neck cancer progression through regulation of the epithelial-mesenchymal transition. Exp Biol Med Maywood. 2023;248:492\u2013500.","journal-title":"Exp Biol Med Maywood"},{"key":"2129_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0092-8674(87)90757-4","volume":"49","author":"H Piwnica-Worms","year":"1987","unstructured":"Piwnica-Worms H, Saunders KB, Roberts TM, Smith AE, Cheng SH. Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src. Cell. 1987;49:75\u201382.","journal-title":"Cell"},{"key":"2129_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-319-91439-8_2","volume":"212","author":"M Lindauer","year":"2018","unstructured":"Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res. 2018;212:29\u201368.","journal-title":"Recent Results Cancer Res"},{"key":"2129_CR36","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Lo Russo P, MacPherson IRJ, Wang D, Morgan JA, Brunton VG, et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009;15:6232\u201340.","journal-title":"Clin Cancer Res"},{"key":"2129_CR37","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0960-9822(95)00060-1","volume":"5","author":"BJ Mayer","year":"1995","unstructured":"Mayer BJ, Hirai H, Sakai R. Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases. Curr Biol. 1995;5:296\u2013305.","journal-title":"Curr Biol"},{"key":"2129_CR38","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/sj.onc.1200954","volume":"14","author":"R Sakai","year":"1997","unstructured":"Sakai R, Nakamoto T, Ozawa K, Aizawa S, Hirai H. Characterization of the kinase activity essential for tyrosine phosphorylation of p130Cas in fibroblasts. Oncogene. 1997;14:1419\u201326.","journal-title":"Oncogene"},{"key":"2129_CR39","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80599-8","volume":"38 Suppl 5","author":"PW Manley","year":"2002","unstructured":"Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer. 2002;38 Suppl 5:S19\u201327.","journal-title":"Eur J Cancer"},{"key":"2129_CR40","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/1541-7786.MCR-13-0396","volume":"12","author":"H Li","year":"2014","unstructured":"Li H, Wawrose JS, Gooding WE, Garraway LA, Lui VWY, Peyser ND, et al. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Mol Cancer Res MCR. 2014;12:571\u201382.","journal-title":"Mol Cancer Res MCR"},{"key":"2129_CR41","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/path.1603","volume":"203","author":"SS Prime","year":"2004","unstructured":"Prime SS, Eveson JW, Stone AM, Huntley SP, Davies M, Paterson IC, et al. Metastatic dissemination of human malignant oral keratinocyte cell lines following orthotopic transplantation reflects response to TGF-beta 1. J Pathol. 2004;203:927\u201332.","journal-title":"J Pathol"},{"key":"2129_CR42","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1016\/j.oraloncology.2009.06.001","volume":"45","author":"L Jiang","year":"2009","unstructured":"Jiang L, Ji N, Zhou Y, Li J, Liu X, Wang Z, et al. CAL 27 is an oral adenosquamous carcinoma cell line. Oral Oncol. 2009;45:e204\u2013207.","journal-title":"Oral Oncol"},{"key":"2129_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1423-0127-16-100","volume":"16","author":"C-Y Chen","year":"2009","unstructured":"Chen C-Y, Chiou S-H, Huang C-Y, Jan C-I, Lin S-C, Tsai M-L, et al. Distinct population of highly malignant cells in a head and neck squamous cell carcinoma cell line established by xenograft model. J Biomed Sci. 2009;16: 100.","journal-title":"J Biomed Sci"},{"key":"2129_CR44","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell. 2017;171:1678\u20131691.e13.","journal-title":"Cell"},{"key":"2129_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061653","volume":"15","author":"JPN Silva","year":"2023","unstructured":"Silva JPN, Pinto B, Monteiro L, Silva PMA, Bousbaa H. Combination Therapy as a Promising Way to Fight Oral Cancer. Pharmaceutics. 2023;15: 1653.","journal-title":"Pharmaceutics"},{"key":"2129_CR46","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1046\/j.1365-2125.1996.36110.x","volume":"41","author":"AE Mackie","year":"1996","unstructured":"Mackie AE, Ventresca GP, Fuller RW, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1996;41:539\u201342.","journal-title":"Br J Clin Pharmacol"},{"key":"2129_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0091-6749(98)70085-5","volume":"102","author":"R Vargas","year":"1998","unstructured":"Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1998;102:191\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"2129_CR48","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1021\/acsbiomaterials.2c00026","volume":"8","author":"VS Madamsetty","year":"2022","unstructured":"Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, Garc\u00eda-Couce J, et al. Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems. ACS Biomater Sci Eng. 2022;8:1763\u201390.","journal-title":"ACS Biomater Sci Eng"},{"key":"2129_CR49","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaci.2013.09.007","volume":"132","author":"RH Oakley","year":"2013","unstructured":"Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol. 2013;132:1033\u201344.","journal-title":"J Allergy Clin Immunol"},{"key":"2129_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/cancers9040039","volume":"9","author":"NJ Rothenberger","year":"2017","unstructured":"Rothenberger NJ, Stabile LP. Hepatocyte Growth Factor\/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers Basel. 2017;9:39.","journal-title":"Cancers Basel"},{"key":"2129_CR51","first-page":"1383","volume":"4","author":"S Giordano","year":"1989","unstructured":"Giordano S, Di Renzo MF, Narsimhan RP, Cooper CS, Rosa C, Comoglio PM. Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene. 1989;4:1383\u20138.","journal-title":"Oncogene"},{"key":"2129_CR52","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1091\/mbc.6.4.371","volume":"6","author":"GJ Den Haese","year":"1995","unstructured":"Den Haese GJ, Walworth N, Carr AM, Gould KL. The Wee1 protein kinase regulates T14 phosphorylation of fission yeast Cdc2. Mol Biol Cell. 1995;6:371\u201385.","journal-title":"Mol Biol Cell"},{"key":"2129_CR53","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.1128\/MCB.25.13.5725-5737.2005","volume":"25","author":"K Katayama","year":"2005","unstructured":"Katayama K, Fujita N, Tsuruo T. Akt\/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2\/M transition. Mol Cell Biol. 2005;25:5725\u201337.","journal-title":"Mol Cell Biol"},{"key":"2129_CR54","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.fct.2018.05.025","volume":"119","author":"H Ge","year":"2018","unstructured":"Ge H, Ke J, Xu N, Li H, Gong J, Li X, et al. Dexamethasone alleviates pemetrexed-induced senescence in Non-Small-Cell Lung Cancer. Food Chem Toxicol. 2018;119:86\u201397.","journal-title":"Food Chem Toxicol"},{"key":"2129_CR55","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41574-023-00843-2","volume":"19","author":"S Starling","year":"2023","unstructured":"Starling S. Glucocorticoid-induced bone loss linked with marrow adipocyte senescence. Nat Rev Endocrinol. 2023;19:312.","journal-title":"Nat Rev Endocrinol"},{"key":"2129_CR56","doi-asserted-by":"publisher","first-page":"16006","DOI":"10.1038\/s41598-018-34475-8","volume":"8","author":"M Patki","year":"2018","unstructured":"Patki M, McFall T, Rosati R, Huang Y, Malysa A, Polin L, et al. Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor. Sci Rep. 2018;8:16006.","journal-title":"Sci Rep"},{"key":"2129_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051821","volume":"7","author":"H Ge","year":"2012","unstructured":"Ge H, Ni S, Wang X, Xu N, Liu Y, Wang X, et al. Dexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancer. PLoS ONE. 2012;7: e51821.","journal-title":"PLoS ONE"},{"key":"2129_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2023.109269","volume":"198","author":"S Srivastava","year":"2023","unstructured":"Srivastava S, Siddiqui S, Singh S, Chowdhury S, Upadhyay V, Sethi A, et al. Dexamethasone induces cancer mitigation and irreversible senescence in lung cancer cells via damaging cortical actin and sustained hyperphosphorylation of pRb. Steroids. 2023;198: 109269.","journal-title":"Steroids"},{"key":"2129_CR59","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.4161\/cc.25622","volume":"12","author":"MK Kullmann","year":"2013","unstructured":"Kullmann MK, Grubbauer C, Goetsch K, J\u00e4kel H, Podmirseg SR, Trockenbacher A, et al. The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells. Cell Cycle. 2013;12:2625\u201335.","journal-title":"Cell Cycle"},{"key":"2129_CR60","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc.2017.53","volume":"17","author":"JMM Levy","year":"2017","unstructured":"Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17:528\u201342.","journal-title":"Nat Rev Cancer"},{"key":"2129_CR61","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.4161\/auto.5.8.10122","volume":"5","author":"D Grand\u00e9r","year":"2009","unstructured":"Grand\u00e9r D, Kharaziha P, Laane E, Pokrovskaja K, Panaretakis T. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. Autophagy. 2009;5:1198\u2013200.","journal-title":"Autophagy"},{"key":"2129_CR62","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41419-022-05503-3","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Han S, Xiao X, An X, Gladkich J, Hinz U, et al. Glucocorticoid-induced microRNA-378 signaling mediates the progression of pancreatic cancer by enhancing autophagy. Cell Death Dis. 2022;13:1052.","journal-title":"Cell Death Dis"},{"key":"2129_CR63","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/15548627.2016.1234563","volume":"13","author":"Y-Q Tan","year":"2017","unstructured":"Tan Y-Q, Zhang J, Zhou G. Autophagy and its implication in human oral diseases. Autophagy. 2017;13:225\u201336.","journal-title":"Autophagy"},{"key":"2129_CR64","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ymthe.2019.01.012","volume":"27","author":"J Xu","year":"2019","unstructured":"Xu J, Su Y, Xu A, Fan F, Mu S, Chen L, et al. miR-221\/222-Mediated Inhibition of Autophagy Promotes Dexamethasone Resistance in Multiple Myeloma. Mol Ther. 2019;27:559\u201370.","journal-title":"Mol Ther"},{"key":"2129_CR65","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1080\/15384047.2015.1016658","volume":"16","author":"L Jiang","year":"2015","unstructured":"Jiang L, Xu L, Xie J, Li S, Guan Y, Zhang Y, et al. Inhibition of autophagy overcomes glucocorticoid resistance in lymphoid malignant cells. Cancer Biol Ther. 2015;16:466\u201376.","journal-title":"Cancer Biol Ther"},{"key":"2129_CR66","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2144\/btn-2019-0044","volume":"67","author":"G SenthilKumar","year":"2019","unstructured":"SenthilKumar G, Skiba JH, Kimple RJ. High-throughput quantitative detection of basal autophagy and autophagic flux using image cytometry. Biotechniques. 2019;67:70\u20133.","journal-title":"Biotechniques"},{"key":"2129_CR67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.metabol.2017.02.005","volume":"71","author":"J Werumeus Buning","year":"2017","unstructured":"Werumeus Buning J, Touw DJ, Brummelman P, Dullaart RPF, van den Berg G, van der Klauw MM, et al. Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial. Metabolism. 2017;71:7\u201316.","journal-title":"Metabolism"},{"key":"2129_CR68","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DRW Jayne","year":"2007","unstructured":"Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"2129_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_100028","volume":"41","author":"NB Leighl","year":"2021","unstructured":"Leighl NB, Nirmalakumar S, Ezeife DA, Gyawali B. An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. Am Soc Clin Oncol Educ Book. 2021;41:1\u201312.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2129_CR70","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018;834:188\u201396.","journal-title":"Eur J Pharmacol"},{"key":"2129_CR71","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116\u201327.","journal-title":"N Engl J Med"},{"key":"2129_CR72","doi-asserted-by":"publisher","first-page":"9627","DOI":"10.18632\/oncotarget.3301","volume":"6","author":"L De Cecco","year":"2015","unstructured":"De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, Bossi P, Locati L, et al. Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. Oncotarget. 2015;6:9627\u201342.","journal-title":"Oncotarget"},{"key":"2129_CR73","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jamaoncol.2016.1790","volume":"3","author":"LGT Morris","year":"2017","unstructured":"Morris LGT, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, et al. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. JAMA Oncol. 2017;3:244\u201355.","journal-title":"JAMA Oncol"},{"key":"2129_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010240","volume":"22","author":"N Kitamura","year":"2020","unstructured":"Kitamura N, Sento S, Yoshizawa Y, Sasabe E, Kudo Y, Yamamoto T. Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2020;22: 240.","journal-title":"Int J Mol Sci"},{"key":"2129_CR75","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1084\/jem.20112160","volume":"208","author":"RA Weiss","year":"2011","unstructured":"Weiss RA, Vogt PK. 100 years of Rous sarcoma virus. J Exp Med. 2011;208:2351\u20135.","journal-title":"J Exp Med"},{"key":"2129_CR76","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41419-022-05224-7","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Zhang X, Hou Z, Cai S, Guo Y, Sun L, et al. P130cas-FAK interaction is essential for YAP-mediated radioresistance of non-small cell lung cancer. Cell Death Dis. 2022;13:783.","journal-title":"Cell Death Dis"},{"key":"2129_CR77","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.4161\/cc.25415","volume":"12","author":"A Pincini","year":"2013","unstructured":"Pincini A, Tornillo G, Orso F, Sciortino M, Bisaro B, Leal MDPC, et al. Identification of p130Cas\/ErbB2-dependent invasive signatures in transformed mammary epithelial cells. Cell Cycle. 2013;12:2409\u201322.","journal-title":"Cell Cycle"},{"key":"2129_CR78","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1158\/0008-5472.CAN-05-2909","volume":"66","author":"S Cabodi","year":"2006","unstructured":"Cabodi S, Tinnirello A, Di Stefano P, Bisar\u00f2 B, Ambrosino E, Castellano I, et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res. 2006;66:4672\u201380.","journal-title":"Cancer Res"},{"key":"2129_CR79","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1096\/fj.10-157347","volume":"24","author":"S Cabodi","year":"2010","unstructured":"Cabodi S, Tinnirello A, Bisaro B, Tornillo G, del Pilar C-L, Forni G, et al. p130Cas is an essential transducer element in ErbB2 transformation. FASEB J. 2010;24:3796\u2013808.","journal-title":"FASEB J"},{"key":"2129_CR80","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.18632\/oncotarget.6710","volume":"7","author":"B Bisaro","year":"2016","unstructured":"Bisaro B, Sciortino M, Colombo S, Camacho Leal MP, Costamagna A, Castellano I, et al. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. Oncotarget. 2016;7:4442\u201353.","journal-title":"Oncotarget"},{"key":"2129_CR81","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","volume":"17","author":"R Guo","year":"2020","unstructured":"Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A. MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020;17:569\u201387.","journal-title":"Nat Rev Clin Oncol"},{"key":"2129_CR82","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","volume":"42","author":"A Puccini","year":"2019","unstructured":"Puccini A, Mar\u00edn-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz H-J, et al. Safety and Tolerability of c-MET Inhibitors in Cancer. Drug Saf. 2019;42:211\u201333.","journal-title":"Drug Saf"},{"key":"2129_CR83","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35:591\u20137.","journal-title":"J Clin Oncol"},{"key":"2129_CR84","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-16-0951","volume":"22","author":"S Hartmann","year":"2016","unstructured":"Hartmann S, Bhola NE, Grandis JR. HGF\/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Clin Cancer Res. 2016;22:4005\u201313.","journal-title":"Clin Cancer Res"},{"key":"2129_CR85","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1093\/hmg\/ddv001","volume":"24","author":"A Sharma","year":"2015","unstructured":"Sharma A, Menche J, Huang CC, Ort T, Zhou X, Kitsak M, et al. A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in asthma. Hum Mol Genet. 2015;24:3005\u201320.","journal-title":"Hum Mol Genet"},{"key":"2129_CR86","doi-asserted-by":"publisher","first-page":"E509","DOI":"10.1152\/ajpendo.2000.278.3.E509","volume":"278","author":"F Blanquaert","year":"2000","unstructured":"Blanquaert F, Pereira RC, Canalis E. Cortisol inhibits hepatocyte growth factor\/scatter factor expression and induces c-met transcripts in osteoblasts. Am J Physiol Endocrinol Metab. 2000;278:E509\u2013515.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2129_CR87","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ijc.27763","volume":"132","author":"A Hoeben","year":"2013","unstructured":"Hoeben A, Martin D, Clement PM, Cools J, Gutkind JS. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma. Int J Cancer. 2013;132:1042\u201350.","journal-title":"Int J Cancer"},{"key":"2129_CR88","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2767-9764.CRC-21-0137","volume":"2","author":"R Kurupi","year":"2022","unstructured":"Kurupi R, Floros KV, Jacob S, Chawla AT, Cai J, Hu B, et al. Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1. Cancer Res Commun. 2022;2:1061\u201374.","journal-title":"Cancer Res Commun"},{"key":"2129_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107615","volume":"300","author":"S Dash","year":"2024","unstructured":"Dash S, Hanson S, King B, Nyswaner K, Foss K, Tesi N, et al. The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas. J Biol Chem. 2024;300: 107615.","journal-title":"J Biol Chem"},{"key":"2129_CR90","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2024.03.029","volume":"186","author":"RL Hollis","year":"2024","unstructured":"Hollis RL, Elliott R, Dawson JC, Ilenkovan N, Matthews RM, Stillie LJ, et al. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Gynecol Oncol. 2024;186:42\u201352.","journal-title":"Gynecol Oncol"},{"key":"2129_CR91","doi-asserted-by":"publisher","unstructured":"Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK, et al. The soft agar colony formation assay. J Vis Exp. 2014;92:e51998. https:\/\/doi.org\/10.3791\/51998.","DOI":"10.3791\/51998"},{"key":"2129_CR92","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1290\/1071-2690(2002)038<0079:CPAFDO>2.0.CO;2","volume":"38","author":"CC Uphoff","year":"2002","unstructured":"Uphoff CC, Drexler HG. Comparative PCR analysis for detection of mycoplasma infections in continuous cell lines. Vitro Cell Dev Biol Anim. 2002;38:79\u201385.","journal-title":"Vitro Cell Dev Biol Anim"},{"key":"2129_CR93","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2023","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2023. Available from: https:\/\/www.R-project.org\/."},{"key":"2129_CR94","doi-asserted-by":"crossref","unstructured":"Ritz C, Baty F, Streibig JC, Gerhard D. Dose-response analysis using R. PLoS One 2015;10. Available from: http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0146021.","DOI":"10.1371\/journal.pone.0146021"},{"key":"2129_CR95","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.21105\/joss.01026","volume":"3","author":"R Vallat","year":"2018","unstructured":"Vallat R. Pingouin: statistics in Python. J Open Source Softw. 2018;3:1026.","journal-title":"J Open Source Softw"},{"key":"2129_CR96","doi-asserted-by":"publisher","unstructured":"team T pandas development. pandas-dev\/pandas: Pandas. Zenodo. 2023. https:\/\/doi.org\/10.5281\/zenodo.8092754.","DOI":"10.5281\/zenodo.8092754"},{"key":"2129_CR97","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","volume":"585","author":"CR Harris","year":"2020","unstructured":"Harris CR, Millman KJ, van der Walt SJ, Gommers R, Virtanen P, Cournapeau D, et al. Array programming with NumPy. Nature. 2020;585:357\u201362.","journal-title":"Nature"},{"key":"2129_CR98","doi-asserted-by":"publisher","unstructured":"Caswell TA, Andrade ES de, Lee A, Droettboom M, Hoffmann T, Klymak J, et al. matplotlib\/matplotlib: REL: v3.7.2. Zenodo. 2023. https:\/\/doi.org\/10.5281\/zenodo.8118151.","DOI":"10.5281\/zenodo.8118151"},{"key":"2129_CR99","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","volume":"6","author":"ML Waskom","year":"2021","unstructured":"Waskom ML. seaborn: statistical data visualization. J Open Source Softw. 2021;6:3021.","journal-title":"J Open Source Softw"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02129-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02129-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02129-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T11:02:54Z","timestamp":1750330974000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02129-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2129"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02129-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.16.618664","asserted-by":"object"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"293"}}